The company, Deep Diamond India Limited, has now transitioned into a pharmaceutical business. The company's new focus is on developing and marketing innovative drugs and therapies that address unmet medical needs in various therapeutic areas.

The company's product portfolio would include prescription drugs, over-the-counter medicines, and medical devices. The company would also collaborate with academic institutions, biotechnology companies, and other pharmaceutical companies to identify and develop new drug targets. The target market for the company's pharmaceutical products includes patients, healthcare professionals, and hospitals. The company also employs marketing and advertising strategies to raise awareness about its products among patients and the general public. The competitive landscape in the pharmaceutical industry is complex and dynamic. The company faces competition from other established pharmaceutical companies as well as emerging biotech companies.

The company has a strategy of developing niche products and new markets that have limited competition and high potential for revenue growth. The pricing policy for the company's pharmaceutical products is based on market demand, manufacturing costs, and regulatory requirements. The company aims to provide affordable and accessible healthcare solutions to patients while ensuring sustainable profitability.

The financial performance of the company is closely monitored and analysed by investors and stakeholders. The company's revenue and profitability depend on factors such as the success of its product development pipeline, regulatory approvals, and market competition.